Physician profile
Dylan A Carroll
NPI 1457814618
$974.83
in general payments reported to CMS, 2019-2025
12 companies · $175 in 2025
The $175 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $125 · 2023: $506 · 2024: $169 · 2025: $175.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $850.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $850.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $180.73 | 2023-2024 | Farxiga, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $129.57 | 2023 | Jardiance |
| Janssen Pharmaceuticals, INC | $124.83 | 2025 | Spravato |
| Glaxosmithkline, LLC. | $124.57 | 2021 | |
| Alkermes, INC. | $119.78 | 2023 | Lybalvi |
| Idorsia Pharmaceuticals US INC | $117.99 | 2023 | Quviviq |
| Novo Nordisk INC | $81.97 | 2024 | Rybelsus, Ozempic |
| Abbvie INC. | $27.72 | 2023 | Vraylar |
| Chiesi USA, INC. | $18.26 | 2025 | Cleviprex |
| Tetraphase Pharmaceuticals, INC. | $17.99 | 2025 | |
| Lilly USA, LLC | $17.48 | 2024 | Jardiance, Zepbound |
| La Jolla Pharmaceutical Company | $13.94 | 2025 | Zevtera |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dylan Carroll listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.